Genocea Gets An Injection Of Capital As Early-Stage Studies Progress
This article was originally published in The Pink Sheet Daily
Executive Summary
The vaccine developer tapped investors for a third round of financing as its lead programs begin clinical trials.
You may also be interested in...
Genocea Aims To Take The T-Cell Century By The Horns
Although cancer grabs the spotlight for harnessing the immune system against tumors, other therapeutic areas and modalities are being developed in the shadows. Genocea Biosciences thinks it has a surefire way to identify novel antigens for T-cell vaccines. It hopes to shake up large infectious disease markets, and more.
Genocea Banking On Success With Herpes Vaccine
Having raised $61 million in its February IPO, Genocea hopes 2015 will be another transformative year for the company, as it expects Phase II data for its herpes simplex virus vaccine, a potential first-in-class product.
Deals of the Week Takes Stock In M&A
Do high biotech share prices portend stock-heavy deal-making in lieu of all-cash transactions? Also, Biogen shares the risk with Eisai in an Alzheimer’s deal, while newly public Genocea and cell therapy specialist NeoStem both teamed with Harvard researchers.